A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder
Status:
Not yet recruiting
Trial end date:
2024-01-26
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate the treatment difference between lemborexant
5 milligram (mg) (LEM5) and placebo (PBO) on latency to persistent sleep (LPS) using
polysomnography (PSG) on Day 30.